Lionsgate Studios (LION) stock slides today after insider sales hit the tape

Lionsgate Studios (LION) stock slides today after insider sales hit the tape

NEW YORK, December 30, 2025, 13:49 ET — Regular session

  • Lionsgate Studios shares fell about 3.4% in Tuesday trading, lagging most media peers.
  • SEC filings showed CEO Jon Feltheimer and Vice Chair Michael Burns sold shares in late December, citing year-end tax planning. SEC+1
  • Traders are watching whether the stock holds the $9 level after a run toward the top of its 52-week range. StockAnalysis

Lionsgate Studios Corp shares fell 3.4% on Tuesday, retreating after filings showed two top executives sold stock late this month. The stock was down 32.5 cents at $9.105, after trading between $9.06 and $9.45.

The disclosures landed with the stock near the top of its 52-week range of $5.55 to $9.46. That has made the name more sensitive to any sign of selling pressure heading into year-end. StockAnalysis

Form 4 filings — mandatory SEC reports that disclose insider buying and selling — can move shares in the short term because they add supply and offer a window into executive behavior. At year-end, those sales often relate to taxes tied to vesting stock awards.

Chief Executive Officer Jon Feltheimer sold 195,000 common shares on Dec. 22 at a weighted average price of $8.28, a Form 4 filing showed. The filing said the transactions were “effected solely for year-end tax planning purposes.” SEC

Vice Chair Michael Burns sold 21,748 common shares on Dec. 23 at a weighted average price of $9.01, according to a separate Form 4. Burns reported beneficial ownership of more than 3 million shares after the sale, a figure that includes restricted stock units, or RSUs — stock awards that convert into common shares as they vest. SEC

The broader market was mostly steady, leaving Lionsgate’s move to stand out as largely stock-specific. The S&P 500 tracker SPY and Nasdaq 100 tracker QQQ were both little changed.

Media and streaming stocks were mixed. Walt Disney was up about 0.9% and Warner Bros. Discovery added about 0.5%, while Netflix dipped about 0.4%.

Investors often treat tax-driven insider sales as a neutral signal, especially when executives retain large positions. But repeated Form 4 headlines can still weigh on the tape, particularly when a stock is near a 52-week high and momentum traders are active.

Lionsgate Studios is the film and television studio behind franchises including “The Hunger Games” and “John Wick,” after Lionsgate moved to separate its studio operations from its Starz business in prior corporate actions. Reuters

The next major catalyst is earnings. Zacks’ earnings calendar lists Lionsgate Studios’ next report for Feb. 5, 2026, keeping attention on any update to the studio’s revenue outlook and path to profitability. Zacks

On valuation, Stock Analysis data show analysts’ average price target sits around $9.11, roughly in line with where the stock traded midday Tuesday. StockAnalysis

Stock Market Today

  • Two under-$10 stocks that could double in 2026: Opendoor Technologies and Sweetgreen
    December 30, 2025, 5:25 PM EST. Two under-$10 names could double in 2026: Opendoor Technologies and Sweetgreen. Through late December, Opendoor was up about 260% in 2025 after a management reshuffle and a turnaround plan aimed at break-even on adjusted net income by year-end 2026. With mortgage rates around 6% and signs housing demand could recover, the stock's upside hinges on macro strength and execution. Sweetgreen faces a tougher year, but easier year-over-year comparisons and potential improvements in same-store sales could spark a rebound if the broader economy cooperates. The prospect of a double is speculative and relies on favorable macro conditions; as of Dec. 29, 14 S&P 500 components had doubled this year.
Natural gas price steadies near $4 as UNG stock climbs; traders await fresh U.S. storage data
Previous Story

Natural gas price steadies near $4 as UNG stock climbs; traders await fresh U.S. storage data

GMAB stock slides as Genmab scraps late-stage acasunlimab cancer therapy
Next Story

GMAB stock slides as Genmab scraps late-stage acasunlimab cancer therapy

Go toTop